Cefoxitin
Second-Generation Cephalosporins
- Drug class
- Second-Generation Cephalosporins
- Availability
- See label
- Routes
- Intramuscular, Intravenous
- Markets covered
- 2
- Products on record
- 8
Overview
Cefoxitin is an active pharmaceutical ingredient in the Second-Generation Cephalosporins group (J01DC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 6 | March 27, 2026 |
| CA Canada | Health Canada | 2 | December 4, 2025 |
GBUnited Kingdom· MHRA
6 products
Uses
Cefoxitin Edgepharma 2 g Powder for Solution for Injection or Infusion is indicated for the treatment of the following infections caused by sensitive bacteria: peritonitis and other intra-abdominal and intrapelvic infections; gonorrhoea; female genital tract infections; septicaemia; urinary tract infections; respiratory tract infections; bone and joint infections; and skin and soft-tissue infections.
‘Cefoxitin Edgepharma 2 g Powder for Solution for Injection or Infusion’ is a broad- spectrum, bactericidal antibiotic indicated for the treatment of infections caused by susceptible strains of Gram-positive and Gram-negative pathogens both aerobic and anaerobic.
‘Cefoxitin Edgepharma 2 g Powder for Solution for Injection or Infusion’ is indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by faecal flora as well as flora originating from the vagina, skin, and mouth.
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Cefoxitin. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL573280002 · revised October 24, 2025
- [2]Health Canada (DPD) · 02128187 · revised December 4, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.